- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07645105
Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or Obesity
The Effect of Body Weight Reduction on Selected Metabolic and Biochemical Parameters in Individuals With Overweight or Obesity
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This was a single-center prospective observational cohort study conducted at the Medical University of Silesia in Katowice, Poland, and in a metabolic outpatient clinic in Miasteczko Śląskie, Poland. The study was designed to evaluate the effect of body weight reduction on selected metabolic, biochemical, oxidative-stress, inflammatory, and body-composition parameters in individuals with overweight or obesity.
The study was conducted in the context of routine metabolic outpatient care. Participants with overweight or obesity received standard lifestyle-based body weight reduction management, including individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits. The investigators did not assign participants to an investigational medicinal product, medical device, dietary supplement, surgical procedure, pharmacological intervention, or experimental therapy. The study prospectively observed participants receiving routine lifestyle-based weight reduction management and assessed changes in clinical and laboratory parameters before and after body weight reduction.
The approved study protocol planned the inclusion of individuals with overweight or obesity and a normal-weight comparison group. Participants with BMI > 25 kg/m² were evaluated in relation to body weight reduction, while individuals with normal body weight served as a comparison group for selected baseline analyses. Patients with overweight or obesity were assessed by medical examination, dietary and clinical questionnaires, anthropometric measurements, body-composition analysis, and fasting blood sampling. Body-composition analysis included assessment of body weight, fat mass, fat-free mass, skeletal muscle mass, total body water, visceral fat, and related parameters. Blood samples were collected for biochemical analyses, including markers of glucose metabolism, lipid metabolism, oxidative stress, antioxidant status, inflammatory markers, adipokines, cytokines, chemokines, growth factors, and selected cardiovascular-risk parameters.
Participants with overweight or obesity were followed during standard body weight reduction management until clinically relevant weight reduction or achievement of optimal body weight. According to the original study documentation, assessments were planned before the start of weight reduction, after approximately 10% body weight reduction, and after approximately 20% body weight reduction or achievement of target body weight. Follow-up visits included body weight measurements, waist and hip circumference measurements, dietary counselling, education regarding caloric intake, and motivation to continue lifestyle modification.
The primary objective of the study was to assess whether body weight reduction in individuals with overweight or obesity is associated with changes in selected metabolic and biochemical parameters. Secondary objectives included evaluation of oxidative-stress and antioxidant-status parameters, glucose and lipid metabolism, inflammatory markers, adipokines, cytokines, and body-composition changes. The study also aimed to assess relationships between biochemical parameters and body-composition indices before and after body weight reduction.
The study was approved by the Bioethics Committee of the Medical University of Silesia in Katowice, Poland. All participants received information about the study and provided written informed consent before participation. This ClinicalTrials.gov record is submitted retrospectively to meet journal publication requirements and to provide transparent public information about the completed study.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Silesian Voivodeship
-
Miasteczko Śląskie, Silesian Voivodeship, Pologne, 42-610
- Eko-Prof-Med Medical Center, Metabolic Outpatient Clinic
-
Zabrze, Silesian Voivodeship, Pologne, 41-808
- Department of Biochemistry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Adults aged 18-85 years
- BMI > 25 kg/m²
- Overweight or obesity diagnosed on the basis of medical examination and body-composition assessment
- Participation in routine lifestyle-based body weight reduction management in a metabolic outpatient clinic
- Written informed consent to participate in the study
Exclusion Criteria:
- Lack of informed consent
- Severe hepatic insufficiency
- Severe renal insufficiency
- Severe respiratory insufficiency
- Severe circulatory insufficiency
- Disturbances of consciousness
- Treatment-resistant depression
- Chronic alcohol abuse
- Pregnancy
- History of serious nervous system injury
- Implanted cardiac pacemaker
- Pharmacological treatment affecting glucose and/or lipid metabolism
- Incomplete follow-up or incomplete laboratory data
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Individuals With Overweight or Obesity
Adults with BMI > 25 kg/m² who were receiving routine lifestyle-based body weight reduction management in a metabolic outpatient clinic.
Participants were prospectively observed and assessed before and after body weight reduction.
Assessments included clinical and dietary questionnaires, anthropometric measurements, body-composition analysis, fasting blood sampling, and biochemical, metabolic, oxidative-stress, inflammatory, adipokine, and cytokine measurements.
|
Standard lifestyle-based body weight reduction management received as part of routine metabolic outpatient care.
It included individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits.
Participants were not assigned to this management as part of the study; the study prospectively observed patients receiving routine care and assessed metabolic, biochemical, inflammatory, oxidative-stress, adipokine, cytokine, and body-composition parameters before and after body weight reduction.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Body Weight
Délai: Baseline and after body weight reduction, up to approximately 6 months
|
Change in body weight from baseline to follow-up after routine lifestyle-based body weight reduction management.
|
Baseline and after body weight reduction, up to approximately 6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Body Fat Mass
Délai: Baseline and after body weight reduction, up to approximately 6 months
|
Change in body fat mass assessed by bioelectrical impedance analysis and expressed in kilograms.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in Glucose concentration in mg/dl.
Délai: Baseline and after body weight reduction, up to approximately 6 months
|
Changes in fasting glucose.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in total-cholesterol concentration in mg/dl.
Délai: Baseline and after body weight reduction, up to approximately 6 months
|
Changes in total cholesterol concentration.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in malondialdehyde concentration in μmol/l.
Délai: Baseline and after body weight reduction, up to approximately 6 months
|
Change in blood malondialdehyde concentration, assessed as a marker of lipid peroxidation and oxidative stress, from baseline to follow-up after body weight reduction.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in serum IL-6 concentration in pg/ml.
Délai: Baseline and after body weight reduction, up to approximately 6 months
|
Change in serum interleukin-6 (IL-6) concentration from baseline to follow-up after body weight reduction.
IL-6 was measured in serum samples as a marker of systemic low-grade inflammation and expressed in pg/ml.
|
Baseline and after body weight reduction, up to approximately 6 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Sławomir Kasperczyk, Prof, Medical University of Silesia in Katowice
Publications et liens utiles
Publications générales
- Szlachta B, Birkova A, Cizmarova B, Glogowska-Gruszka A, Zalejska-Fiolka P, Dydon M, Zalejska-Fiolka J. Erythrocyte Oxidative Status in People with Obesity: Relation to Tissue Losses, Glucose Levels, and Weight Reduction. Antioxidants (Basel). 2024 Aug 7;13(8):960. doi: 10.3390/antiox13080960.
- Szlachta B, Birkova A, Wielkoszynski T, Gospodarczyk A, Hubkova B, Dydon M, Zalejska-Fiolka J. Serum Oxidative Status in People with Obesity: Relation to Tissue Losses, Glucose Levels, and Weight Reduction. Antioxidants (Basel). 2023 Oct 27;12(11):1923. doi: 10.3390/antiox12111923.
- Zalejska-Fiolka J, Birkova A, Hubkova B, Wielkoszynski T, Cizmarova B, Szlachta B, Fiolka R, Blaszczyk U, Wylegala A, Kasperczyk S, Grzanka A, Marekova M, Toborek M. Successful correction of hyperglycemia is critical for weight loss and a decrease in cardiovascular risk in obese patients. J Nutr Biochem. 2022 Aug;106:109021. doi: 10.1016/j.jnutbio.2022.109021. Epub 2022 Apr 25.
- Zalejska-Fiolka J, Birkova A, Wielkoszynski T, Hubkova B, Szlachta B, Fiolka R, Blaszczyk U, Kuzan A, Gamian A, Marekova M, Toborek M. Loss of Skeletal Muscle Mass and Intracellular Water as Undesired Outcomes of Weight Reduction in Obese Hyperglycemic Women: A Short-Term Longitudinal Study. Int J Environ Res Public Health. 2022 Jan 17;19(2):1001. doi: 10.3390/ijerph19021001.
- Zalejska-Fiolka J, Hubkova B, Birkova A, Velika B, Puchalska B, Kasperczyk S, Blaszczyk U, Fiolka R, Bozek A, Maksym B, Marekova M, Birkner E. Prognostic Value of the Modified Atherogenic Index of Plasma during Body Mass Reduction in Polish Obese/Overweight People. Int J Environ Res Public Health. 2018 Dec 27;16(1):68. doi: 10.3390/ijerph16010068.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Troubles nutritionnels
- Maladies métaboliques
- Suralimentation
- Poids
- Troubles du métabolisme du glucose
- Résistance à l'insuline
- Hyperinsulinisme
- Conditions pathologiques, signes et symptômes
- Maladies nutritionnelles et métaboliques
- Signes et symptômes
- En surpoids
- Obésité
- Syndrome métabolique
- Obésité abdominale
- Abdominal obesity metabolic syndrome
Autres numéros d'identification d'étude
- KNW/0022/KB1/19/I/16
- Secondary ID: KNW-1-016/N/7/2 (Autre subvention/numéro de financement: Medical University of Silesia)
- Secondary ID: KNW-1/109/K/8/Z (Autre identifiant: Medical University of Silesia)
- Secondary ID: KNW-1/171/K/9/O (Autre identifiant: Medical University of Silesia)
- Secondary ID: PCN-1-049/K/0/O (Autre identifiant: Medical University of Silesia)
- Secondary ID: PCN-1-018/K/1/O (Autre identifiant: Medical University of Silesia)
- Secondary ID: PCN-1-132/K/2/O (Autre identifiant: Medical University of Silesia)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .